FDA approves ESR1-targeted breast cancer therapy
The U.S. Food and Drug Administration (FDA) has approved a new drug combination for the treatment of advanced breast cancer in patients harboring a genetic mutation called ESR1, which in some cases is associated with resistance to hormone therapy. The treatment involves a combination of two drugs: the first is imlunestrant, which targets estrogen receptors, and the second is abemaciclib, which inhibits the CDK4 and CDK6 enzymes and halts cancer cell division. Results from the EMBER-3 trial, involving 874 patients, showed that adding abemaciclib to hormone therapy increased the median progression-free survival from 5.5 to 11.1 months in patients with the ESR1 mutation. The therapy is used after confirming the presence of the mutation through an approved test, with the aim of controlling the disease and prolonging the period during which the cancer is kept under control, although it is not considered a definitive cure. Side effects may include decreased blood cell counts, diarrhea, and nausea, necessitating regular monitoring. This approval marks a significant development in cancer treatment in 2026, reflecting a trend toward personalized therapy based on the tumor's molecular characteristics.
Notice: This Is an AI-Generated Summary
Comments (0)